SPRY

SEC source: 0001415889-24-008172 · form4-03152024_110359.xml · nonDerivative · entry 6

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,696,494

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F4 · price: The weighted average sale price for the transaction reported was $9.1415, and the range of prices were between $9.01 and $9.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F2 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 7

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 1,998,499

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F5 · price: The weighted average sale price for the transaction reported was $9.1413, and the range of prices were between $9.02 and $9.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

SEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 6

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,696,494

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F4 · price: The weighted average sale price for the transaction reported was $9.1415, and the range of prices were between $9.01 and $9.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided

F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-008172 · form4-03152024_110359.xml · nonDerivative · entry 5

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,046,960

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.

SEC source: 0001415889-24-008172 · form4-03152024_110359.xml · nonDerivative · entry 4

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,744,789

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 5

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,046,960

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

SEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 4

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,744,789

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-008172 · form4-03152024_110359.xml · nonDerivative · entry 3

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,047,199

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.

SEC source: 0001415889-24-008172 · form4-03152024_110359.xml · nonDerivative · entry 2

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,744,994

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 3

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,047,199

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

SEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 2

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,744,994

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006188 · form4-03022024_010328.xml · nonDerivative · entry 4

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,747,447

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F6 · price: The weighted average sale price for the transaction reported was $9.0190, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F7 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001415889-24-006188 · form4-03022024_010328.xml · nonDerivative · entry 3

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,048,499

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F4 · price: The weighted average sale price for the transaction reported was $9.0144, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

SEC source: 0001415889-24-006188 · form4-03022024_010328.xml · nonDerivative · entry 2

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,746,494

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2 · price: The weighted average sale price for the transaction reported was $9.0188, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006187 · form4-03022024_010345.xml · nonDerivative · entry 4

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,747,447

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F6 · price: The weighted average sale price for the transaction reported was $9.0190, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F7 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose

SEC source: 0001415889-24-006187 · form4-03022024_010345.xml · nonDerivative · entry 3

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,048,499

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F4 · price: The weighted average sale price for the transaction reported was $9.0144, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.

SEC source: 0001415889-24-006187 · form4-03022024_010345.xml · nonDerivative · entry 2

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,746,494

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2 · price: The weighted average sale price for the transaction reported was $9.0188, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 7

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,748,447

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F7 · price: The weighted average sale price for the transaction reported was $9.0205, and the range of prices were between $9.00 and $9.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F4 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 6

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,050,481

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F6 · price: The weighted average sale price for the transaction reported was $9.0212, and the range of prices were between $9.00 and $9.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

SEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 5

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,747,294

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F5 · price: The weighted average sale price for the transaction reported was $9.0205, and the range of prices were between $9.00 and $9.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-005790 · form4-02292024_020233.xml · nonDerivative · entry 7

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,748,447

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F7 · price: The weighted average sale price for the transaction reported was $9.0205, and the range of prices were between $9.00 and $9.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F4 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose

SEC source: 0001415889-24-005790 · form4-02292024_020233.xml · nonDerivative · entry 6

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,050,481

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F6 · price: The weighted average sale price for the transaction reported was $9.0212, and the range of prices were between $9.00 and $9.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.

SEC source: 0001415889-24-005790 · form4-02292024_020233.xml · nonDerivative · entry 5

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,747,294

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F5 · price: The weighted average sale price for the transaction reported was $9.0205, and the range of prices were between $9.00 and $9.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F2 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 4

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020

Disclosed balance after: 1,772,750

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F4 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 3

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,099,500

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

SEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 2

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,772,750

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-005790 · form4-02292024_020233.xml · nonDerivative · entry 4

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020

Disclosed balance after: 1,772,750

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F4 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose

SEC source: 0001415889-24-005790 · form4-02292024_020233.xml · nonDerivative · entry 3

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Disclosed balance after: 2,099,500

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.

SEC source: 0001415889-24-005790 · form4-02292024_020233.xml · nonDerivative · entry 2

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,772,750

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001209191-24-000825 · doc4.xml · derivative · entry 8

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2034-01-01

F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-24-000825 · doc4.xml · derivative · entry 7

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 880,000

Underlying: Common Stock · 880,000 shares

Expires 2034-01-01

F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-24-000818 · doc4.xml · derivative · entry 1

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-24-000815 · doc4.xml · derivative · entry 8

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 880,000

Underlying: Common Stock · 880,000 shares

Expires 2034-01-01

F5 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-24-000815 · doc4.xml · derivative · entry 7

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2034-01-01

F5 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-24-000810 · doc4.xml · derivative · entry 1

Dorsey Brian · CIK 0001380762 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-24-000806 · doc4.xml · derivative · entry 1

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-24-000805 · doc4.xml · derivative · entry 1

Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-24-000804 · doc4.xml · derivative · entry 1

Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-051073 · doc4.xml · nonDerivative · entry 2

Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,227

F3 · price: The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.70 to $3.85, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-23-051073 · doc4.xml · nonDerivative · entry 1

Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,969

F1 · price: The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.60 to $3.64, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · balance_after: Includes 2,969 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2023.

SEC source: 0001104659-23-103529 · tm2326846-1_4seq1.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,556,774

F3 · price: This transaction was executed in multiple trades at prices ranging from $3.75 to $3.90; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes, upon request, to provide full information to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected.

F4 · balance_after: Held directly by the Fund.

F4 · ownership.nature: Held directly by the Fund.

F6 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-23-103529 · tm2326846-1_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,365,465

F1 · price: This transaction was executed in multiple trades at prices ranging from $2.75 to $3.74; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes, upon request, to provide full information to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected.

F2 · balance_after: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F6 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001209191-23-048254 · doc4.xml · derivative · entry 5

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,235

Underlying: Common Stock · 97,003 shares

Expires 2030-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-048254 · doc4.xml · derivative · entry 4

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,997 shares

Expires 2030-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-048254 · doc4.xml · nonDerivative · entry 3

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 210,346

F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.24 to $8.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.

SEC source: 0001209191-23-048254 · doc4.xml · nonDerivative · entry 2

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 310,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-048254 · doc4.xml · nonDerivative · entry 1

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,343

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000947871-23-000915 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director

ORBIMED CAPITAL LLC · CIK 0001157524 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 8,019,187

F1 · kind: These shares of the Issuer's common stock were purchased in a private transaction pursuant to the terms of a Stock Purchase Agreement.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.

F5 · ownership.nature: Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001104659-23-097327 · tm2325196-1_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 5,856,774

F1 · shares: On August 29, 2023, the Fund (as defined in footnote (2)) entered into a contract to purchase the shares from a third-party seller in a privately negotiated transaction.

F2 · balance_after: These shares are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: These shares are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000947871-23-000914 · ownership.xml · nonDerivative · entry 1

Thompson Peter A. · CIK 0001357522 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 8,019,187

F1 · kind: These shares of the Issuer's common stock were purchased in a private transaction pursuant to the terms of a Stock Purchase Agreement.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.

F5 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, and OrbiMed Capital is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.